Resultats globals: 4 registres trobats en 0.01 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
15 p, 3.4 MB Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS / Kuendgen, A. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ; Garcia-Manero, G. (Department of Leukemia. MD Anderson Cancer Center) ; Komrokji, R.S. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Sekeres, M.A. (Leukemia Program. Department of Hematology and Medical Oncology. Taussig Cancer Institute. Cleveland Clinic) ; Della Porta, M.G. (Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University) ; Cazzola, M. (Department of Hematology Oncology. IRCCS Policlinico San Matteo Foundation) ; DeZern, A.E. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University) ; Roboz, G.J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ; Steensma, D.P. (Dana-Farber Cancer Institute) ; Van de Loosdrecht, A.A. (Vrije Universiteit Amsterdam) ; Schlenk, R.F. (Department of Internal Medicine V. Heidelberg University Hospital) ; Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Blum, S. (Service of Hematology. University Hospital Lausanne) ; Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valent, P. (Department of Internal Medicine I. Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ; Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giagounidis, A. (Department of Oncology. Hematology and Palliative Care. Marienhospital Duesseldorf) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Döhner, H. (Department of Internal Medicine III. University Hospital Ulm) ; Platzbecker, U. (University Hospital Leipzig) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Lübbert, M. (Department of Hematology. Oncology and Stem Cell Transplantation. University Medical Center Freiburg. Faculty of Medicine) ; Oiartzabal, I. (Clinical Hematology Department. Hospital Universitario Araba) ; Díez-Campelo, M. (Clinical Hematology Department. Hospital Universitario de Salamanca (HUSA)) ; Cedena, M.T. (Hospital Universitario 12 de Octubre (Madrid)) ; Machherndl-Spandl, S. (1st. Internal Department - Hematology with stem cell transplants. Hemostaseology and Medical Oncology. Elisabethinen Hospital) ; López-Pavía, M. (Clinical Hematology Department. Hospital General Universitari de València) ; Baldus, C.D. (Department of Hematology and Oncology. University Hospital Schleswig-Holstein. Campus Kiel) ; Martinez-de-Sola, M. (Parc Taulí Hospital Universitari) ; Stauder, R. (Department of Internal Medicine V (Hematology and Oncology). Innsbruck Medical University) ; Merchan, B. (Hospital Universitari Vall d'Hebron) ; List, A. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Ganster, C. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Schroeder, T. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Voso, M.T. (Department of Biomedicine and Prevention. Tor Vergata University) ; Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ; Sill, H. (Medizinische Universität Graz) ; Hildebrandt, B. (Institute of Human Genetics. University Duesseldorf) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cobo, F. (Clinical Hematology Department. Hospital Quirón Teknon) ; Haas, R. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Germing, U. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Greenberg, P.L. (Stanford University Cancer Center) ; Haase, D. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Sanz, G. (Hospital Universitari i Politècnic La Fe de Valencia) ; Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020  
2.
14 p, 1.9 MB Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine / Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Borrás, Josep (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Marcé, Sílvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Jiménez, Maria José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Guàrdia, Ramón (Hospital Universitari de Girona Doctor Josep Trueta) ; Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa) ; Garcia, Antoni (Hospital Arnau de Vilanova (Lleida)) ; Feliu, Evarist (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. [...]
2018 - 10.18632/oncotarget.25046
Oncotarget, Vol. 9 (april 2018) , p. 19342-19355  
3.
8 p, 1.4 MB The expression level of BAALC -associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia / Díaz-Beyá, Marina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Nomdedéu, J (Institut d'Investigació Biomèdica Sant Pau) ; Cordeiro, A (Universitat de Barcelona. Facultat de Medicina) ; Tormo, M (Hospital Clínic i Provincial de Barcelona) ; Escoda, L (Hospital Universitari Joan XXIII de Tarragona) ; Ribera, J M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Arnan, M (ICO, Hematology Department, Hospital Duran i Reynals, l'Hospitalet de Llobregat) ; Heras, Inmaculada (Hematology Department, Hospital Morales Meseguer) ; Gallardo Giralt, David (Hospital Universitari de Girona Doctor Josep Trueta) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Queipo de Llano, M P (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Salamero, O (Hospital Universitari Vall d'Hebron) ; Martí, J M (Hospital Universitari MútuaTerrassa) ; Sampol, A (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Hoyos, M (Institut d'Investigació Biomèdica Sant Pau) ; Pratcorona, M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Castellano, J J (Universitat de Barcelona. Facultat de Medicina) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Risueño, R M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sierra, J (Institut d'Investigació Biomèdica Sant Pau) ; Monzó, M (Universitat de Barcelona. Facultat de Medicina) ; Navarro, A (Universitat de Barcelona. Facultat de Medicina) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. [...]
2015 - 10.1038/bcj.2015.76
Blood Cancer Journal, Vol. 5 (october 2015) , p. e352  
4.
7 p, 184.9 KB Trisomy 8, a cytogenetic abnormality in Myelodysplastic Syndromes, is constitutional or not? / Saumell i Tutusaus, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ; Solé Ristol, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ; Montoro Gómez, Julia (Hospital Universitari Vall d'Hebron) ; Valcarcel Ferreiras, David (Hospital Universitari Vall d'Hebron) ; Pedro, Carme (Institut Hospital del Mar d'Investigacions Mèdiques) ; Sanzo, Carmen (Hospital Universitario Central de Asturias (Oviedo)) ; Luño, Elisa (Hospital Universitario Central de Asturias (Oviedo)) ; Giménez, Teresa (Hospital Universitari Joan XXIII de Tarragona) ; Arnan, Montserrat (Institut Català d'Oncologia) ; Pomares, Helena (Institut Català d'Oncologia) ; De Paz, Raquel (Hospital Universitario La Paz (Madrid)) ; Arrizabalaga, Beatriz (Hospital Universitario Cruces (Barakaldo, Biscaia)) ; Jerez, Andrés (Hospital General Universitario Morales Meseguer (Múrcia)) ; Martínez, Ana B. (Hospital General Universitario Morales Meseguer (Múrcia)) ; Sánchez-Castro, Judith (Hospital Universitari Arnau de Vilanova (Lleida, Catalunya)) ; Rodríguez-Gambarte, Juan D. (Hospital Universitario Ramón y Cajal (Madrid)) ; Raya, José M. (Hospital Universitario de Canarias (Santa Cruz de Tenerife)) ; Ríos, Eduardo (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Rodríguez-Rivera, María (Hospital del Mar (Barcelona, Catalunya)) ; Espinet i Solà, Blanca (Hospital del Mar (Barcelona, Catalunya)) ; Florensa, L. (Hospital del Mar (Barcelona, Catalunya))
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). [...]
2015 - 10.1371/journal.pone.0129375
PloS one, Vol. 10, No 6 (June 2015) , p. e0129375  

Vegeu també: autors amb noms similars
4 Pedro, Carme
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.